Adjusted EBT
The Adjusted EBITDA Total for continuing operations amounted to € 1,266.5 million in the first six months of 2024 and was thus 2.6% lower than the prior-year value of € 1,299.8 million in the first six months of 2023.
In the 2024 reporting period, the non-recurring items eliminated in the Adjusted EBT came to € 45.4 million (6M 2023: € 119.2 million). The following table gives a detailed list of the non-recurring items:
Non-recurring Items
Non-recurring Items | ||||||||
in € million | H1 2023 | H1 2024 | Change in % | 12M 2023 | ||||
Transactions* | 82.9 | 12.9 | -84.4 | 70.0 | ||||
Personnel matters | 26.6 | 14.7 | -44.7 | 35.1 | ||||
Business model optimization | 6.2 | 14.4 | >100 | 34.9 | ||||
Research & development | 3.4 | 2.9 | -14.7 | 6.8 | ||||
Refinancing and equity measures | 0.1 | 0.5 | >100 | 1.1 | ||||
Total non-recurring items | 119.2 | 45.4 | -61.9 | 147.9 | ||||
- *Including one-time expenses in connection with acquisitions, such as HR measures relating to the integration process and other follow-up costs.